Lenvatinib Induces Immunogenic Cell Death and Triggers Toll-Like Receptor-3/4 Ligands in Hepatocellular Carcinoma.
Cheng ZhouZhang-Fu YangBao-Ye SunYong YiZheng WangJian ZhouJia FanWei GanNing RenShuang-Jian QiuPublished in: Journal of hepatocellular carcinoma (2023)
. Antibodies against PD-1/PD-L1 can enhance the efficacy of lenvatinib in the management of hepatocellular carcinoma.